By Fineline Cube AbbVie Inc. (NYSE: ABBV), the US pharmaceutical giant, has announced a strategic partnership with the China unit of Santen Pharmaceutical Co., Ltd., a global leader in ophthalmology. The agreement grants Santen exclusive distribution and promotion rights for AbbVie’s portfolio of five glaucoma eye drops in mainland China.
Deal Framework
| Item | Detail |
|---|---|
| Licenser | AbbVie Inc. (NYSE: ABBV) |
| Licensee | Santen Pharmaceutical Co., Ltd. (China Unit) |
| Products | Alphagan, Alphagan P, Lumigan, Ganfort, and Combigan |
| Indication | Glaucoma and ocular hypertension |
| Territory | Mainland China |
| Term | 6 years |
| Rights Granted | Exclusive distribution and promotion |
Strategic Rationale
This partnership leverages Santen’s unparalleled commercial infrastructure and deep expertise in the Chinese ophthalmic market to maximize the reach and impact of AbbVie’s established glaucoma franchise. Glaucoma is a leading cause of irreversible blindness in China, with a large and growing patient population, representing a significant market opportunity.
For AbbVie, the deal provides a capital-efficient route to ensure its key ophthalmic products maintain strong market presence and patient access in China without the need for a dedicated sales force. For Santen, adding these five well-known and clinically validated products to its portfolio significantly strengthens its position as the dominant player in the Chinese glaucoma therapeutic segment.
The six-year term provides stability and a clear runway for both parties to execute a coordinated commercial strategy in one of the world’s most important healthcare markets.-Fineline Info & Tech